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Effect of Trazodone on Upper Airway Resistance in Chronic Spinal Cord Injury
Geoffrey Ginter, Sean Carroll, Abdulghani Sankari, M. Safwan Badr
Background:
Spinal cord injury (SCI) is a known risk factor for sleep-disordered breathing. While device-based
therapies such as CPAP are beneficial in these individuals, adherence to these treatments is often low;
consequently, pharmacotherapies for sleep-disordered breathing in patients with SCI are in high
demand. Trazodone is an atypical antidepressant with a complex mechanism of action, including alpha
adrenergic agonist activity and inhibition of serotonin reuptake. Serotonin (5-HT) is a known modulator
of respiratory circuitry, which has been shown to influence the ventilatory drive. Trazodone is commonly
prescribed as a sleep aid, but its impact on breathing during sleep is still unclear.
Methods:
We randomized 9 participants with chronic spinal cord injury and sleep-disordered breathing to receive
either placebo or trazodone 100 mg for seven days. On day 7, participants underwent polysomnography
with a supraglottic pressure catheter to determine upper airway pressure. Participants then underwent
a 1-week washout period before crossing over to the other medication and repeating the same protocol.
Parameters of interest included apnea-hypopnea index (AHI), obstructive apnea index (OAI), central
apnea index (CAI), oxyhemoglobin desaturation index (ODI), and upper airway resistance (RUA).
Results:
7 participants completed polysomnography on both medications, 5 of which had adequate data to
calculate RUA. Trazodone did not result in significant improvement in AHI (47.86±24.27 on placebo vs
28.73±28.79 on trazodone, p=0.10), OAI (9.29±9.48 vs 2.86±3.39, p=0.13), CAI (1.14±1.46 vs 1.71±3.30,
p=0.52), ODI (25.00±28.39 vs 19.44±33.61, p=0.34), or RUA (2.47±0.92 vs 8.98±11.02, p=0.23).
Conclusion:
Based on our preliminary data in a small number of subjects, trazodone is not effective in treating sleepdisordered breathing in individuals with spinal cord injury. Due to the limited sample size, our data may
not accurately represent the clinical utility of trazodone, and further study in a larger number of patients
is warranted.

